Boehringer Ingelheim/Pfizer's Spiriva gets FDA panel nod for exacerbations claim
This article was originally published in Scrip
Executive Summary
The US FDA's pulmonary-allergy drugs advisory panel has endorsed adding a claim to Boehringer Ingelheim's long-acting anticholinergic Spiriva HandiHaler (tiotropium bromide; licensed to Pfizer) for reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).